Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Eisai Expands Deal with Arena, Gets All Global Rights to Belviq
January 6, 2017
- Kyowa Kirin’s KRN23 Filed in Europe for X-Linked Hypophosphatemia
January 6, 2017
- SSP Now under Sanofi Group in Japan after BI Biz Swap
January 6, 2017
- ASKA Eyes 33% Rise in Women’s Health Sales by FY2020
January 5, 2017
- ASKA Ties Up with TesoRx on Oral Testosterone Therapy
January 5, 2017
- Takeda Makes Foray into Consumer Diagnostic Biz with Ovulation, Pregnancy Tests
December 28, 2016
- Opdivo Filed for Gastric Cancer in Japan: Ono
December 28, 2016
- AZ Returns Meropenem Rights in Southeast Asia, HK to Sumitomo Dainippon
December 27, 2016
- SBI, Kubota to Form JV for Ophthalmic Drugs, Devices
December 27, 2016
- Aspen Japan to Launch Imigran AG on Jan. 16
December 27, 2016
- 40 Billion Yen Sales for Oncology Business in FY2020 Achievable: Daiichi Sankyo
December 27, 2016
- Towa to Discontinue Marketing Cabergoline Generic due to Failure in Dissolution Testing
December 27, 2016
- Eisai, Keio Univ. Seal 10-Year Collaboration on Dementia Research
December 26, 2016
- Ono In-Licenses OmniAb Antibody Producing Platforms from US Biotech
December 26, 2016
- Chugai Licenses Marine-Derived Cancer Med from Spain’s PharmaMar
December 26, 2016
- Hemophilia Med Emicizumab Hits PIII Target; Global Filings Slated for 2017
December 26, 2016
- Keytruda Filed for Hodgkin’s Lymphoma, 3rd Indication in Japan
December 26, 2016
- Sawai Prevails in Patent Suit over Elplat
December 26, 2016
- New Indication Added to Plavix Generics to Fill Gap with Originator
December 22, 2016
- Janssen’s MM Med Daratumumab Filed in Japan
December 22, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…